Tourani, Jean-Marc <br/><br/>
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Nov 2003 
 - 3987-94 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2003.02.073  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Ambulatory Care<br/>Antineoplastic Agents--administration & dosage<br/>Blood Sedimentation<br/>Carcinoma, Renal Cell--drug therapy<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>France<br/>Humans<br/>Injections, Subcutaneous<br/>Interferon-alpha--administration & dosage<br/>Interleukin-2--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Prognosis<br/>Survival Analysis<br/>Treatment Outcome